You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

liver and intrahepatic biliary tract cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer Trial in Duarte (procedure, other, drug)

Active, not recruiting
  • Breast Cancer
  • +11 more
  • radionuclide imaging
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Oct 20, 2022

Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma Trial

Recruiting
  • Metastatic Distal Bile Duct Adenocarcinoma
  • +9 more
  • Atezolizumab
  • +6 more
  • Phoenix, Arizona
  • +28 more
Dec 31, 2022

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

LIver, Biliary tRAct and pancReatic Cancers

Recruiting
  • Liver Cancer
  • +2 more
  • Blood drawing
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital, Zhejiang University School of Me
Nov 14, 2023

Biliary Tract Diseases, Gallbladder Cancer, Extrahepatic Bile Duct Cancer Trial (no interventions)

Not yet recruiting
  • Biliary Tract Diseases
  • +5 more
  • no interventions
  • (no location specified)
Jun 1, 2023

European Training Program for Robotic Liver Surgery (LIVEROBOT)

Not yet recruiting
  • Liver Diseases
  • +6 more
  • European Multicentre Training Program for Robotic Liver Surgery
  • (no location specified)
Feb 8, 2023

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,

Recruiting
  • Biliary Tract Cancer (CCA)
  • +4 more
  • Frankfurt am Main, Germany
    Krankenhaus Nordwest
Jun 23, 2022

Multi-Platform Profiling of Resected Biliary Tract Cancer

Recruiting
  • Biliary Tract Cancer
  • +7 more
  • Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
  • Chicago, Illinois
  • +1 more
Jan 23, 2023

Intrahepatic Cholangiocarcinoma Trial in Germany (Durvalumab, Tremelimumab)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Dresden, Germany
  • +7 more
Apr 13, 2022

Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma Trial in Rochester (Irinotecan,

Active, not recruiting
Has Results
  • Advanced Bile Duct Carcinoma
  • +17 more
  • Rochester, Minnesota
    Mayo Clinic
Jan 5, 2023

Observational Monocentric Study on Biliary Tract Cancer (BABEL)

Recruiting
  • Biliary Tract Cancer
    • Roma, Rome, Italy
      Fondazione Policlinico Universitario Agostino Gemelli/IRCSS - UO
    Jul 10, 2023

    Advanced Biliary Tract Cancer Trial in Tianjin (Cadonilimab+Regorafenib+GC)

    Not yet recruiting
    • Advanced Biliary Tract Cancer
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital Airport Hospital
    Apr 7, 2023

    Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

    Not yet recruiting
    • Advanced Biliary Tract Cancer
    • (no location specified)
    Apr 11, 2023

    Advanced Biliary Tract Cancer Trial (anlotinib+TQB2450+nab-paclitaxel+cisplatin)

    Not yet recruiting
    • Advanced Biliary Tract Cancer
    • (no location specified)
    Apr 2, 2023

    Biliary Tract Tumors, Gallbladder Cancer, Cholangiocarcinoma Trial in Seoul (Durvalumab + Gem/Cis, Gem/Cis)

    Active, not recruiting
    • Biliary Tract Neoplasms
    • +2 more
    • Seoul, Korea, Republic of
      Asan Medical Center
    Jan 30, 2023

    Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer Trial in Seongnam-si (nab-paclitaxel plus gemcitabine-cisplatin)

    Recruiting
    • Biliary Tract Cancer
    • +2 more
    • nab-paclitaxel plus gemcitabine-cisplatin
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
      CHA Bundang Medical Center
    Oct 27, 2022

    Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance Study -

    Not yet recruiting
    • Biliary Tract Cancer
      • (no location specified)
      Apr 26, 2023

      Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

      Recruiting
      • Advanced Biliary Tract Cancer
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 22, 2023

      Biliary Tract Cancer Trial in Seoul (Pemetrexed 500 MG, Erlotinib)

      Recruiting
      • Biliary Tract Cancer
      • Seoul, Korea, Republic of
      • +1 more
      Jun 13, 2022

      Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

      Recruiting
      • Biliary Tract Neoplasms
      • Immunotherapy
      • Beijing, Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Jul 6, 2023

      Biliary Tract Cancer Trial (GEN-001, Pembrolizumab, mFOLFOX)

      Not yet recruiting
      • Biliary Tract Cancer
      • (no location specified)
      Aug 16, 2023

      HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Colorectal Cancer
      • HER2-positive Biliary Tract Cancer
      • Beijing, State*, China
        Peking University cancer hospital & institution
      Aug 2, 2023

      AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary

      Recruiting
      • Biliary Tract Cancer
      • Blood drawing
      • Guangzhou, Guangdong, China
      • +1 more
      Dec 28, 2022

      Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

      Not yet recruiting
      • Locally Advanced Biliary Tract Cancer
      • Metastatic Biliary Tract Cancer
      • Camrelizumab and Apatinib Plus GP
      • Guangzhou, Guangdong, China
        Cancer center of SunYat-sen University
      Feb 15, 2023